AstraZeneca

Ultime notizie

Titoli nella lingua originale della fonte.

• 
  AstraZeneca deepens Summit ties on ADC-bispecific cancer combo testing pact (si apre in una nuova scheda)

  Pharmaceutical Technology · 2 ott 2026

• 
  Sanofi, Regeneron Expand Immunology Alliance With New Antibodies (si apre in una nuova scheda)

  Zacks · 2 ott 2026

• 
  Summit Teams Up With Daiichi Sankyo, AstraZeneca For Cancer Therapy Trial – CEO Calls It An ‘Important Expansion’ (si apre in una nuova scheda)

  Stocktwits · 2 ott 2026

• 
  J&J's Innovative Medicine Segment in Q3: Key Growth Drivers to Watch (si apre in una nuova scheda)

  Zacks · 2 ott 2026

• 
  Summit Therapeutics (SMMT), What Is Behind The Fresh Attention? (si apre in una nuova scheda)

  Simply Wall St. · 2 ott 2026

• AstraZeneca and Daiichi Sankyo Partner with Summit Therapeutics to Study Datopotamab Deruxtecan and Ivonescimab (si apre in una nuova scheda)

  Oncodaily · 2 ott 2026

• AstraZeneca, Daiichi Partner With Summit on Cancer-Drug Trials (si apre in una nuova scheda)

  Bloomberg.com · 2 ott 2026

• AstraZeneca, Daiichi Sankyo and Summit Therapeutics Plan Datroway–Ivonescimab Combination Trials (si apre in una nuova scheda)

  Yahoo Finance UK · 2 ott 2026

• AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination (si apre in una nuova scheda)

  Reuters · 2 ott 2026

• AstraZeneca, Daiichi Sankyo collaborate with Summit Therapeutics to evaluate Datroway-ivonescimab combo (si apre in una nuova scheda)

  Seeking Alpha · 2 ott 2026

• AstraZeneca and Daiichi Sankyo announce clinical collaboration with Summit Therapeutics to evaluate Datroway in combination with ivonescimab across multiple tumour types (si apre in una nuova scheda)

  AstraZeneca · 2 ott 2026

• 
  Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway (si apre in una nuova scheda)

  Business Wire · 2 ott 2026

• Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types (si apre in una nuova scheda)

  Business Wire · 2 ott 2026

• 
  AstraZeneca (AZN) Puts $2 Billion Into Summit Therapeutics (SMMT) for a Cancer Tie-Up (si apre in una nuova scheda)

  Insider Monkey · 2 ott 2026

• 
  What Does Summit Therapeutics (SMMT) Gain From This $2 Billion Cancer Partnership? (si apre in una nuova scheda)

  Simply Wall St. · 1 ott 2026

• 
  Cellectis Unveils In Vivo Gene-Editing Plans for Severe Lipid Disorders (si apre in una nuova scheda)

  MarketBeat · 1 ott 2026

• Hong Kong needs new funding model to attract global drug makers: AstraZeneca (si apre in una nuova scheda)

  South China Morning Post · 1 ott 2026

• 
  700,000 Seniors Have Started GLP-1s Through Medicare. Now AstraZeneca Just Moved a Once-Daily Pill Into Phase 3 (si apre in una nuova scheda)

  24/7 Wall St. · 30 set 2026

• AstraZeneca slips Wednesday, underperforms market (si apre in una nuova scheda)

  MarketWatch · 30 set 2026

• AstraZeneca’s $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets (si apre in una nuova scheda)

  30 set 2026

• AstraZeneca's $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets (si apre in una nuova scheda)

  24/7 Wall St. · 30 set 2026

• Hansoh’s Tagrisso rival loses EU approval after AstraZeneca legal challenge (si apre in una nuova scheda)

  Fierce Pharma · 30 set 2026

• AstraZeneca Dealt Latest Loss in Arkansas Drug Discount Case (si apre in una nuova scheda)

  Bloomberg Law News · 30 set 2026

• AstraZeneca commits $2bn to advance ADC combination medicines for cancer (si apre in una nuova scheda)

  European Pharmaceutical Review · 30 set 2026

• 
  Drug Repurposing Market - Global Strategic Business Report: Forecasts Growth to $37.3Billion by 2030, Profiling AbbVie, AstraZeneca, Pfizer, Novartis & Johnson & Johnson (si apre in una nuova scheda)

  GlobeNewswire · 30 set 2026

• AstraZeneca (LSE:AZN) Wins FDA Priority Review For IMFINZI In Bladder Cancer (si apre in una nuova scheda)

  30 set 2026

• AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll (si apre in una nuova scheda)

  BioSpace · 30 set 2026

• Is AstraZeneca (LSE:AZN) Undervalued Following Its New Lung Cancer FDA Filing? (si apre in una nuova scheda)

  Yahoo Finance · 30 set 2026

• AstraZeneca boards the PD-1/VEGF ship with $2B Summit investment (si apre in una nuova scheda)

  european-biotechnology.com · 30 set 2026

• AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up (si apre in una nuova scheda)

  Reuters · 30 set 2026